KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Receivables (2016 - 2025)

Historic Receivables for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $11.6 billion.

  • Teva Pharmaceutical Industries' Receivables rose 3779.65% to $11.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.6 billion, marking a year-over-year increase of 3779.65%. This contributed to the annual value of $11.6 billion for FY2025, which is 3779.65% up from last year.
  • Teva Pharmaceutical Industries' Receivables amounted to $11.6 billion in Q4 2025, which was up 3779.65% from $3.8 billion recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Receivables peaked at $11.6 billion during Q4 2025, and registered a low of $3.4 billion during Q1 2025.
  • In the last 5 years, Teva Pharmaceutical Industries' Receivables had a median value of $3.7 billion in 2022 and averaged $4.5 billion.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 2084.54% in 2023, then skyrocketed by 14734.53% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Receivables (Quarter) stood at $4.5 billion in 2021, then dropped by 18.39% to $3.7 billion in 2022, then fell by 7.77% to $3.4 billion in 2023, then surged by 147.35% to $8.4 billion in 2024, then soared by 37.8% to $11.6 billion in 2025.
  • Its Receivables stands at $11.6 billion for Q4 2025, versus $3.8 billion for Q3 2025 and $3.6 billion for Q2 2025.